Mucosal Healing

Vedolizumab not only induced endoscopic improvements in patients with chronic pouchitis, but also appeared to improve clinical outcomes at week 34, especially in those who achieved mucosal healing at week 14, research showed.

Biweekly infusions of olamkicept 600 mg increased the likelihood of clinical response and mucosal healing at 12 weeks in patients with active ulcerative colitis compared with placebo, according to results published in JAMA.

IV risankizumab followed by maintenance therapy induced sustained improvement in endoscopic outcomes in patients with moderate to severe Crohn’s disease, according to research presented at ECCO.

The Crohn’s disease exclusion diet with or without enteral nutrition induced and maintained remission in adult patients with mild to moderate CD and may lead to full endoscopic remission.

Higher ustekinumab trough concentration levels correlated with increased rates of endoscopic remission among patients with Crohn’s disease, according to research published in BMC Gastroenterology.

In a real-world Crohn’s disease population, biologic- naive patients, compared with biologic-experienced patients, had a significantly greater chance for achieving mucosal healing, according to research at Digestive Disease Week.